Jiangsu Hengrui Medicine (Hengrui Medicine) and Fox Chase Cancer Center began discussions as Hengrui Medicine contemplates opening clinical trials in the United States. Founded in 1970, Hengrui Medicine is the largest publicly listed biopharma company based in China with more than 15,000 employees and 2,000 scientists. Hengrui Medicine has three new molecular entities approved in China, three applications under China NDA, as well as 25+ programs in clinical development across oncology, anesthesiology & pain management, autoimmune, and metabolic & cardiovascular diseases. Hengrui Therapeutics, based in Princeton NJ, was founded in 2016 as a $100 million joint venture between Hengrui Medicine and a leading global investment firm, with the goal of developing and commercializing a selected portion of the Hengrui Medicine pipeline in the United States.
About Our Partnership
Confidentiality Agreement - details are confidential and cannot be disclosed to the public.
